Navigation Links
Amylin Announces Preliminary Results of Annual Meeting of Stockholders
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that, based on a preliminary vote count provided by its proxy solicitor, shareholders voted to elect at least 10 of the Company's nominees, including its two new independent nominees, Paul N. Clark and Paulo F. Costa, to Amylin's Board of Directors at the Company's Annual Meeting of Stockholders held today. The Company believes that no more than two of the five dissident nominees (one independent nominee from Eastbourne Capital Management, L.L.C. and one nominee from Carl Icahn) have been elected to Amylin's Board. Additionally, Mr. Icahn's proposal to reincorporate the Company from Delaware to North Dakota has been defeated.

The Company issued the following statement:

We appreciate the consideration and support of our shareholders, as well as the valuable insights offered to our Board and management team over the past several months. Today's outcome affirms that shareholders have confidence in the Company's plan to build value in 2009 and beyond, having apparently elected only two of the five dissident nominees.

We remain deeply committed to building long-term value for all of our shareholders, especially through the anticipated launch of exenatide once weekly, our investigational therapy that has the potential to significantly advance the treatment of type 2 diabetes. We thank all of our Directors for their tremendous commitment and contributions to Amylin. Our Board and management team will work with the new Directors to continue to bring transformational medicines to patients and maximize shareholder value.

IVS Associates, Inc., the independent Inspector of Elections, has indicated that it expects to issue a preliminary tabulation of the vote results early next week. Final results of the Annual Meeting will be announced once they are certified by the Inspector following the customary review and challenge period.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

Forward Looking Statements

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, such as the exenatide once weekly NDA mentioned in this press release, may not be submitted timely or receive FDA approval; risks that our expense reductions will not be as large as we expect; risks that the restructured operations for exenatide will not produce the results we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company's most recently filed Form 10-K and Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

    CONTACTS:

    Alice Izzo
    Executive Director, Corporate Affairs
    Amylin Pharmaceuticals, Inc.
    (858) 642-7272
    alice.izzo@amylin.com

    or

    Steve Frankel / Averell Withers
    Joele Frank, Wilkinson Brimmer Katcher
    (212) 355-4449


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
Breaking Medicine Technology: